MULti-Tumour based prediction and manipulation of Immune Response

Informazioni relative al progetto

MULTIR

ID dell’accordo di sovvenzione: 101136926

DOI

10.3030/101136926

Data della firma CE 7 Dicembre 2023

Data di avvio 1 Gennaio 2024

Data di completamento 31 Dicembre 2027

Finanziato da

• Health

Costo totale

€ 8 547 711,50

Contributo UE

€ 8 547 711,50

Coordinato da

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France

CORDIS fornisce collegamenti ai risultati finali pubblici e alle pubblicazioni dei progetti ORIZZONTE.

I link ai risultati e alle pubblicazioni dei progetti del 7° PQ, così come i link ad alcuni tipi di risultati specifici come dataset e software, sono recuperati dinamicamente da .OpenAIRE .

Risultati finali

Documents, reports (3)

Policy brief formulating recommendations based on the research and innovation strand of the “Understanding (tumour-host interactions)”annual cluster meeting
Dissemination plan

Dissemination plan defined (updated M24)

Stakeholder engagement plan

Multi-stakeholder engagement plan defined

Websites, patent fillings, videos etc. (2)

Common video and brochure for the “Understanding (tumour-host interactions)” cluster

A common video and a brochure for the “ Understanding (tumour-host interactions)” cluster will be produced in collaboration with the other projects of the cluster

Launch of the website

Website open to the public

Pubblicazioni

Conference proceedings (3)

Abstract 2190: Genomic scarring score is associated with T cell exhaustion in early stage non small cell lung cancer

Autori: Ioannis Pateras, Konstantinos Ntostoglou, Georgios Christodoulopoulos, Katerina Tsilingiri, Anna Chalari, Giannis Vatsellas, Georgia Christopoulou, Pantelis Constantoulakis, Eleni Patsea, Konstantinos Potaris, Ioannis Vamvakaris, Dora Chatzidaki, Georgina Zachou, Athanasios Kotsakis, Apostolos Klinakis, Vassilis Georgoulias
Pubblicato in: Cancer Research, Numero 85, 2025, ISSN 0008-5472
Editore: American Association for Cancer Research (AACR)
DOI: 10.1158/1538-7445.AM2025-2190

1233P Genomic scarring score as a criterion for PARP inhibitor administration in early-stage NSCLC

Autori: A. Klinakis, K. Tsilingiri, A. Chalari, A. Voutsina, G. Christopoulou, G. Vatselas, K. Potaris, I. Vamvakaris, D. Hatzidaki, G. Zachou, V. Georgoulias, P. Konstantoulakis, A. Kotsakis
Pubblicato in: Annals of Oncology, Numero 35, 2024, ISSN 0923-7534
Editore: Elsevier BV
DOI: 10.1016/J.ANNONC.2024.08.1292

Abstract 2919: Homologous recombination deficiency in non-small cell lung cancer: genetic and epigenetic causes beyond HRR

Autori: Katerina Tsilingiri, Anna Chalari, Georgia Christopoulou, Alexandra Voutsina, Pantelis Constantoulakis, Konstantinos Potaris, Ioannis Vamvakaris, Dora Hatzidaki, Georgina Zachou, Giannis Vatsellas, Vassilis Georgoulias, Athanasios Kotsakis, Apostolos Klinakis
Pubblicato in: Cancer Research, Numero 85, 2025, ISSN 0008-5472
Editore: American Association for Cancer Research (AACR)
DOI: 10.1158/1538-7445.AM2025-2919

Peer reviewed articles (4)

Cell-specific models reveal conformation-specific RAF inhibitor combinations that synergistically inhibit ERK signaling in pancreatic cancer cells

Autori: Thomas Sevrin, Hiroaki Imoto, Sarah Robertson, Nora Rauch, Uscinnia Dyn’ko, Katerina Koubova, Kieran Wynne, Walter Kolch, Oleksii S. Rukhlenko, Boris N. Kholodenko
Pubblicato in: Cell Reports, Numero 43, 2024, ISSN 2211-1247
Editore: Elsevier BV
DOI: 10.1016/J.CELREP.2024.114710

Genomic scarring score predicts the response to PARP inhibitors in non-small cell lung cancer

Autori: Katerina Tsilingiri, Anna Chalari, Georgia Christopoulou, Alexandra Voutsina, Pantelis Constantoulakis, Κonstantinos Potaris, Ioannis Vamvakaris, Dora Hatzidaki, Georgina Zachou, Giannis Vatsellas, Vassilis Georgoulias, Athanasios Kotsakis, Apostolos Klinakis
Pubblicato in: npj Precision Oncology, Numero 8, 2024, ISSN 2397-768X
Editore: Springer Science and Business Media LLC
DOI: 10.1038/S41698-024-00777-6

Cell State Transition Models Stratify Breast Cancer Cell Phenotypes and Reveal New Therapeutic Targets

Autori: Oleksii S. Rukhlenko, Hiroaki Imoto, Ayush Tambde, Amy McGillycuddy, Philipp Junk, Anna Tuliakova, Walter Kolch, Boris N. Kholodenko
Pubblicato in: Cancers, Numero 16, 2025, ISSN 2072-6694
Editore: MDPI AG
DOI: 10.3390/CANCERS16132354

cSTAR analysis identifies endothelial cell cycle as a key regulator of flow-dependent artery remodeling

Autori: Hanqiang Deng, Oleksii S. Rukhlenko, Divyesh Joshi, Xiaoyue Hu, Philipp Junk, Anna Tuliakova, Boris N. Kholodenko, Martin A. Schwartz
Pubblicato in: Science Advances, Numero 11, 2025, ISSN 2375-2548
Editore: American Association for the Advancement of Science (AAAS)
DOI: 10.1126/SCIADV.ADO9970